Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its cancer-drug pipeline through the acquisition of UK-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Novartis has reached an agreement to acquire Myricx Bio. The deal is valued at up to $1.5 billion, with Fierce Biotech reporting an upfront payment of $1.1 billion.
Coverage from Bloomberg, the Wall Street Journal, and the Financial Times emphasizes the transaction's scale and Myricx Bio's status as a UK biotech firm. The move is aimed at expanding Novartis's antibody-drug conjugate (ADC) pipeline, according to Fierce Biotech.
Future developments center on the integration of Myricx Bio's cancer-drug research into the Novartis pipeline.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What is the total value of the acquisition?
The deal is valued at up to $1.5 billion.
How much is Novartis paying upfront?
According to Fierce Biotech, Novartis will pay $1.1 billion upfront.
Why is Novartis acquiring Myricx Bio?
The acquisition is intended to expand Novartis's ADC pipeline.
Coverage (6)
- Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion qz.com · 8h ago
- Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis Business Wire · 8h ago
- Novartis to buy UK biotech Myricx Bio in $1.5bn deal Financial Times · 8h ago
- Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline Fierce Biotech · 8h ago
- Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion Bloomberg.com · 8h ago
- Novartis to Buy Myricx Bio for Up to $1.5 Billion WSJ · 8h ago broke it first
People, places & organizations
Topics
Related trends
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs
Scribe Therapeutics files for $75 million IPO to test public appetite for early-stage biotechs
Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
French biotech Ipsen is acquiring Kartos Therapeutics in a deal valued at up to $1.75 billion to expand its hemato-oncology pipeline.